Oral formulation researchers work in the Department of Oral Formulation Research in Global Research Technologies. Currently, most of our therapeutic peptides and proteins are injectable, but we aim to make more oral products available to our patients in the future.
Our oral formulation researchers play a key role in Novo Nordisk’s R&D strategy, as they are responsible for developing new oral peptide and protein formulations that will feed the R&D pipeline in all our therapeutic areas.
Our oral formulation researchers are responsible for identifying new, innovative oral drug delivery systems for the oral drug project portfolio. Specifically, they formulate therapeutic peptides and proteins into orally available products, such as tablets.
They are also responsible for solid-state characterisation and analysis of both drug product intermediates and the final drug product.
Formulation researchers work very early in the R&D value chain. They perform early research activities, identify oral formulations for our therapeutic peptides and proteins, and find compositions and processes by which these formulations can be made.
Once a suitable formulation has been identified, tested, and found to fulfil the given target product profile, the composition and process are transferred to CMC Development, where the formulation will be further upscaled and manufactured for clinical trials.